- 3billion attends ESHG 2026, one of the world’s leading human genetics conferences
- AI-powered services for rare disease diagnosis, family-based genomic testing, and newborn screening
- Strong interest in genomic testing for prevention and early diagnosis
South Korea, June 16, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it showcased its AI-powered genetic testing services at the European Human Genetics Conference (ESHG 2026), held in Gothenburg, Sweden, from June 13 to 16
Organized by the European Society of Human Genetics (ESHG), the European Human Genetics Conference is widely regarded as one of the world’s leading international meetings in human genetics. It brings together geneticists, clinicians, and researchers from around the world to share the latest research findings and advances in clinical practice
At ESHG 2026, 3billion presented its expanding portfolio and long-term roadmap, extending from rare disease diagnosis to preventive genomic healthcare. The event marked the company’s first participation in a major international genetics conference since expanding beyond patient-focused diagnostics to serve newborns and families
3billion recently launched Family Insight, a family-based precision genomic testing service, and 3B-NEO, a genomic newborn screening service. With these services, the company is expanding its focus from shortening diagnostic odysseys to identifying genetic risks earlier and supporting more proactive care. Clinicians and researchers expressed strong interest in how the services can support early diagnosis, treatment planning, and proactive health management
At the conference, 3billion also gained firsthand insight into challenges facing healthcare systems worldwide, including gaps in diagnostic infrastructure and limited access to genetic testing. Discussions with attendees highlighted demand and market potential for preventive genomic testing. Based on these insights, the company plans to expand services tailored to local healthcare environments and strengthen engagement with healthcare providers, public institutions, and consumers as it grows its presence in the global genomic testing market.
“ESHG 2026 provided a valuable opportunity to hear directly from healthcare professionals and explore long-term growth opportunities,” said Changwon Keum, CEO of 3billion. “We will continue expanding beyond diagnosis into prevention and proactive health management, with the goal of growing into an AI-powered genomic testing company that supports people at every stage of life.”
Get exclusive rare disease updatesfrom 3billion
3billion Inc
3billion is dedicated to creating a world where patients with rare diseases are not neglected in diagnosis and treatment
Read More from This Author
